- Home
- AGIO vs FORM Comparison
AGIO vs FORM Comparison
Compare AGIO & FORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- FORM
- Stock Information
- Founded
- AGIO 2007
- FORM 1993
- Country
- AGIO United States
- FORM United States
- Employees
- AGIO N/A
- FORM N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- FORM Semiconductors
- Sector
- AGIO Health Care
- FORM Technology
- Exchange
- AGIO Nasdaq
- FORM Nasdaq
- Market Cap
- AGIO 2.4B
- FORM 2.7B
- IPO Year
- AGIO 2013
- FORM N/A
- Fundamental
- Price
- AGIO $40.72
- FORM $38.70
- Analyst Decision
- AGIO Strong Buy
- FORM Buy
- Analyst Count
- AGIO 5
- FORM 8
- Target Price
- AGIO $57.25
- FORM $38.14
- AVG Volume (30 Days)
- AGIO 577.5K
- FORM 1.0M
- Earning Date
- AGIO 10-30-2025
- FORM 10-29-2025
- Dividend Yield
- AGIO N/A
- FORM N/A
- EPS Growth
- AGIO N/A
- FORM N/A
- EPS
- AGIO 11.13
- FORM 0.57
- Revenue
- AGIO $40,875,000.00
- FORM $764,554,000.00
- Revenue This Year
- AGIO $23.76
- FORM $2.58
- Revenue Next Year
- AGIO $148.23
- FORM $7.33
- P/E Ratio
- AGIO $3.67
- FORM $68.31
- Revenue Growth
- AGIO 30.57
- FORM 8.30
- 52 Week Low
- AGIO $23.42
- FORM $22.58
- 52 Week High
- AGIO $62.58
- FORM $50.79
- Technical
- Relative Strength Index (RSI)
- AGIO 63.66
- FORM 61.98
- Support Level
- AGIO $39.32
- FORM $34.80
- Resistance Level
- AGIO $41.42
- FORM $40.86
- Average True Range (ATR)
- AGIO 1.34
- FORM 1.78
- MACD
- AGIO 0.34
- FORM 0.47
- Stochastic Oscillator
- AGIO 87.58
- FORM 57.00
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About FORM FormFactor Inc. FormFactor Inc.
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.